Tensive Controls, Inc. Announces new name, Endevica Bio
March 2021. Executive Chairman, Russell Potterfield announces that this will be the first of many milestones the company will achieve this year.
Article published in Drug Discovery & Development
Marks joins the Board of Directors
February 2021. Dr. Dan Marks, longtime researcher in the field of Cachexia, joins the Board of Directors.
New publication in JCI
New publication in JCSM
New Executive Chairman
January 2020. Russell Potterfield is named Executive Chairman of the Board of Directors of Tensive Controls, Inc.
Transition to Phase 2 of NIH Grant
June 2017. TCI Peptide’s demonstrated progress toward development path milestones and successfully transitioned to Phase 2 of the National Cancer Institute Grant.
Nationwide Clinical Trial Opened
May 2017. Clinical trial sites from major veterinary hospital groups were opened to augment recruitment efforts at the University of Missouri School of Veterinary Medicine.
NIH Grant Awarded
September 2016. TCI Peptide’s was awarded a $2.3 million grant from the National Cancer Institute to further advance research and development of a melanocortin-based therapeutic for cancer cachexia.
September 2016. The USPTO issued a Notice of Allowance for a patent application protecting the company’s technology platform.
September 2016. The EPO granted a European Patent for the company’s application dealing with suppression of cardiovascular side effects in melanocortin analogs intended for therapeutic and related uses.
Series A Completed
June 2016. TCI Peptide’s completed a $1.7 million financing round through Centennial Investors Angel Investor Network. Funds will be used to advance the development of applications of the company’s technology platform for modifying peptides with applications in human and animal health.